Initial LiquiBandT product in

RNS Number : 9428A

Advanced Medical Solutions Grp PLC

16 October 2009

 



For immediate release

16 October 2009

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Initial LiquiBand™ product introduced to US market

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that LiquiBand™ topical skin adhesive, the initial product for which the Group received regulatory clearance in February, has been introduced to the US market by MedLogic, its wound closure and sealants division. Further LiquiBand® products are under review by the FDA.  

LiquiBand™, the leading topical skin adhesive in the UK accident and emergency market received 510(k) clearance from the US Food & Drug Administration (FDA) earlier this year, and is indicated for use on trauma induced lacerations, minor wounds and laparoscopic skin incisions.

The product line consisting of LiquiBand and LiquiBand™ Flow Control was unveiled at the American College of Emergency Physicians in Boston, 5-8 October and is being displayed at the American Academy of Pediatrics National Conference and Exposition in Washington DC, 17-20 October .

Commenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, stated:

"We are thrilled to bring this exciting technology to clinicians and patients in the United States.  LiquiBand™ has been sold successfully for many years in Europe and has enabled MedLogic to establish a leadership position in the use of tissue adhesives for wound closure.

"The products shown at the Emergency Physicians meeting and at the Pediatrics Conference will be commercially available in November via multiple distribution partners and further products will follow to provide a comprehensive suite of products to allow us to compete strongly in the US topical tissue adhesives market currently estimated at around $200m."

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel: [phone]
Buchanan Communications
Mark Court / Stasa Filiplic	Tel: [phone]
Investec Bank plc	Tel: [phone]
Tim Pratelli / Daniel Adams

  Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its in-house technology to provide a vertically integrated 'one stop shop' for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

AMS' technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS' products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

 

END

 

 

NRAMFBATMMMBBTL